Table 1. Histopathological re-examination results for individuals discordant for ER and HER2 status between routine pathology and sequencing-based analysis.
| Medical record |
Seq-based characterization |
Re-examination by IHC/SISH |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID | Discordant marker | ER | HER2 | ER | HER2 | HER2 copy-number* | subtype | ER% | HER2 IHC | ER | HER2 | HER2 SISH | Concordant after re-examination |
| RDK1 | ER | + | − | − | − | Basal | 0 | 0 | − | Y | |||
| RDK2 | ER | − | − | + | − | LumA | 100 | 0–1+ | + | Y | |||
| RDL1 | ER | + | − | − | − | Basal | 0 | 0 | − | Y | |||
| RDL2 | ER | + | − | − | − | Basal | 0 | 0 | − | Y | |||
| RDL3 | ER | + | − | − | − | Her2 | 0 | 2+ | − | Y | |||
| RDL4 | ER | + | + | − | + | Her2 | 0 | 3+ | − | Y | |||
| RDK3 | ER | + | + | − | + | Her2 | 20 | 3+ | + | N | |||
| RDL5-a | ER | + | NA | − | + | Her2 | 20 | 3+ | + | N | |||
| RDL5-b | ER | + | NA | − | + | Her2 | 80 | 2+ | + | N | |||
| RDL6 | ER | + | − | − | − | Her2 | 15 | 0 | + | N | |||
| RDL7 | ER/HER2 | + | − | − | + | low amp | LumA | 100 | 1+ | + | − | NA | N/N |
| RDL8-a | HER2 | + | + | + | − | low amp | LumB | 80 | 0 | + | − | NA | Y |
| RDL9 | HER2 | − | − | − | + | high amp | Her2 | 0 | 3+ | − | + | NA | Y |
| RDL10 | HER2 | + | + | + | − | low amp | LumB | 100 | 1+ | + | + | positive | N |
| RDL8-b | HER2 | + | + | + | − | low amp | LumB | 90 | 1+ | + | + | positive | N |
| RDL11 | HER2 | + | + | + | − | low amp | LumB | 85 | 1+–2+ | + | + | positive | N |
| RDL12 | HER2 | + | + | + | − | low amp | LumB | 100 | 3+ | + | + | NA | N |
*See Supplemental Figures 3–8.
NA = missing/unavailable data.
Patients RDL5 and RDL8 had two separate tumor pieces re-examined by IHC/SISH (labeled as −a and −b)
(Key: LumA = Luminal A, LumB = Luminal B, Her2 = Her2-enriched, Basal = Basal-like).